By: Melissa Gonzales – President, Women’s Health, Myriad Genetics 

When the big moment comes and parents learn they are having a baby, life changes and anticipation runs high.  For many parents, learning the sex of their little one is at the top of their wish list.  And they want that information to be quick and accurate, so they can share the news with loved ones and make plans for a healthy, happy pregnancy.   

Today, Myriad Genetics took a significant step to help parents on this journey, acquiring Gateway Genomics, a leader in personal genomics and developer of the No. 1 selling SneakPeek® Early Gender DNA Test. SneakPeek reveals a baby’s gender at just six weeks into pregnancy from home with 99% accuracy — the earliest method yet!  More than four million visitors frequent the SneakPeek website. It’s the best selling DNA test on Amazon and the top searched gender test on Google with strong brand loyalty, high online ratings, reviews and likelihood to recommend.  

The acquisition is a tangible example of how we are investing to bring relevant genetic information to consumers in a way that is accessible, affordable, and easy to use, enabling parents to know as much as possible about their baby as soon as possible.  I could not be more excited to have our new Gateway Genomics teammates as part of Myriad Genetics as we expand our offerings in Women’s Health to better serve consumers and clinicians and expand access to genetic insights for all.  

Learning the sex of your baby is even more meaningful when it’s part of a full care continuum that empowers parents with personalized, data-driven medical information. Research by Gateway Genomics shows 60% of women who take SneakPeek go on to non-invasive prenatal testing (NIPS) to determine if a pregnancy is at an increased risk for common chromosome abnormalities, such as down syndrome.   

Now we can interact with consumers even earlier and support with them with additional testing such as our Prequel™ non-invasive prenatal screen and ForeSight™ carrier screen.  This is critical since we know that less than 50% of women receive NIPS and carrier testing today and there are nearly four million pregnancies per year. We continue our support with the MyRisk™ Hereditary Cancer Test with RiskScore® for all ancestries, helping people take control of their health and make informed decisions with their healthcare providers so they can watch their children grow.  

All of this expands the opportunity to educate, inform and engage in new ways.  I could not be more excited about it.  SneekPeak fits seamless into our Women’s Health portfolio.

Myriad Genetics and Gateway Genomics share a common vision to expand health and well-being for all, increasing access to easier, more affordable and accessible genetic testing.  We are excited to welcome Gateway Genomics and their entire team to Myriad and look forward to continuing our innovation journey together, illuminating the path to better health through genetic insights!  

Myriad Genetics at J.P. Morgan Healthcare Conference

Paul J. Diaz, president and chief executive officer, Bryan Riggsbee, chief financial officer, and Dale Muzzey, chief scientific officer, presented at the 41st annual J.P. Morgan (JPM) Healthcare Conference.